Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Anne Prener is Director at Keros Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Nov 16, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
1
Anne Prener has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Anne Prener reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $5.6K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Keros TherapeuticsKROS
3 disclosures · Jul 2026 – Nov 2026 · 1 sold
Nov 12, 2026Sold~$5.6Kdisclosed Nov 16
DetailsOfficial recordJul 1, 202614Kdisclosed Jul 6
DetailsOfficial recordJul 1, 202615Kdisclosed Jul 6
DetailsOfficial recordAs of the latest filing on , Anne Prener reported holding 13,212 shares of Keros Therapeutics (KROS), worth about $133K at the last close of $10 (Nov 16, 2026). In the last 12 months, Anne Prener sold $5.6K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Keros Therapeutics KROS | 13,212 | 13K direct | $10 | $133K | Nov 12, 2026 |
Is this Anne Prener’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Anne Prener reported 0 open-market purchases and 1 sale here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 12, 2026, Anne Prener reported holding 13,212 shares of Keros Therapeutics (KROS). At the last close of $10 on Nov 16, 2026, that is about $133K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Anne Prener reported 1 open-market sale worth $5.6K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Anne Prener has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Keros Therapeutics (KROS), from 2026 to 2026: 0 purchases and 1 sale.